NCI National Clinical Trials Network (NCTN) Program Guidelines

PART 2: Submission of Competing New Applications Section I - Application Submission Instructions
B. Initial Communications and Letter of Intent
Initial Communications with NCI/DCTD Staff – 4 to 6 Months Before Application Due Date:
Although it is not required, it is strongly recommended that prospective applicants schedule a preapplication
consultation with NCI/DCTD Program Staff including the Lead NCTN Program Director and
appropriate Scientific Program/Project Officers (i.e., Co-Program Directors for specific components of
the NCTN) approximately four (4) to six (6) months in advance of the application due date. This
consultation is intended to help the Principal Investigator (along with multiple Principal Investigators
and/or co-investigators) to clarify the NCTN application and discuss all relevant aspects of the
application process. NCI/DCTD staff will clarify the intent of the Guidelines and current NCI budget
allocations, and describe the peer-review process. To schedule the pre-application consultation,
prospective applicants should send a request to the NCI/DCTD Senior Program Specialist for the NCTN
electronically or by mail:
NCI/DCTD Senior Program Specialist for the NCTN:
Elise Kreiss, MSW, MBA
Office of the Associate Director, Cancer Therapy Evaluation Program
National Cancer Institute
6130 Executive Boulevard, Room 7018, MSC 7340
Bethesda, MD 20892-7340 (for U.S. Postal Service regular or Express Mail)
Rockville, MD 20852 (for non-USPS delivery)
Telephone: 301-402-0427
Email: ncictepanalyst@mail.nih.gov
Letter of Intent – 30 Days Before Application Due Date:
Although a Letter of Intent is not required, is not binding, and does not enter into the review of a
subsequent application, the information that it contains allows NCI staff to estimate the potential
review workload and plan the review. By the date listed in the table provided under “General
Considerations and Due Dates” in Part 2 – Section I.A in these Guidelines, prospective applicants are
asked to submit a Letter of Intent that includes the following information:
� Descriptive title of proposed research
� Name, address, and telephone number of the Program Director(s)/Principal Investigator(s)
� Names of other key personnel
� Participating institutions
� Number and title of the Funding Opportunity Announcement/Request for Application
The Letter of Intent should be sent to:
NCTN Lead Program Director:
Meg Mooney, MD
Clinical Investigations Branch, Cancer Therapy Evaluation Program
National Cancer Institute
6130 Executive Boulevard, Room 7024, MSC 7340
Bethesda, MD 20892-7340 (for U.S. Postal Service regular or Express Mail)
Rockville, MD 20852 (for non-USPS delivery)
Telephone: 301-496-2522
Email: ncictepanalyst@mail.nih.gov
C. Application Submission Procedures
Applications must be prepared using the PHS 398 research grant application forms and instructions
(unless they have converted to electronic submission) for preparing a research grant application.
Submit a signed, typewritten original of the application, including the checklist, and three (3) signed
Page 96 of 241